EBITDA: Income before interest, taxes, depreciation and amortization.
Outlook Therapeutics, Inc. (OTLK) had EBITDA of $-10.80M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$0.01M |
|
$-20.32M |
|
$0.02M |
|
$-0.01M |
|
$10.82M |
|
$-10.81M |
|
$-9.51M |
|
$-20.32M |
|
$-20.32M |
|
$-20.32M |
|
$-20.32M |
|
$-20.32M |
|
$-20.32M |
|
$-10.81M |
|
|
EBITDA |
$-10.80M |
136.74M |
|
136.74M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$23.17M |
|
-- |
|
$3.02M |
|
$26.18M |
|
$28.68M |
|
-- |
|
$7.90M |
|
$36.58M |
|
$-10.39M |
|
$-10.39M |
|
$-10.39M |
|
187.10M |
|
| Cash Flow Statement Financials | |
$-43.78M |
|
$-2.10M |
|
$49.04M |
|
$8.08M |
|
$11.24M |
|
$3.16M |
|
$2.43M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.81 |
|
-- |
|
-- |
|
-- |
|
-1.75 |
|
-95.00% |
|
-124255.30% |
|
-124255.30% |
|
-- |
|
-233554.80% |
|
-233554.80% |
|
$-43.78M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
0.01 |
|
0.02M |
|
195.52% |
|
195.52% |
|
-77.60% |
|
195.52% |
|
$-0.06 |
|
$-0.32 |
|
$-0.32 |
|